enGene Holdings Inc. Common Stock (ENGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) has a cash flow conversion efficiency ratio of -0.103x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.90 Million) by net assets ($281.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See enGene Holdings Inc. Common Stock defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
enGene Holdings Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
enGene Holdings Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of enGene Holdings Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TTEC Holdings Inc
NASDAQ:TTEC
|
0.269x |
|
Tat Gida Sanayi AS
IS:TATGD
|
0.249x |
|
Tunghsu Azure Renewable Energy Co Ltd
SHE:000040
|
0.016x |
|
Control Print Limited
NSE:CONTROLPR
|
0.065x |
|
Star Holdings
NASDAQ:STHO
|
-0.030x |
|
Provident Financial Holdings Inc
NASDAQ:PROV
|
0.015x |
|
Spyrosoft Spólka Akcyjna
F:2NP
|
0.126x |
|
Tillys Inc
NYSE:TLYS
|
0.101x |
Annual Cash Flow Conversion Efficiency for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of enGene Holdings Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of enGene Holdings Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $167.71 Million | $-99.24 Million | -0.592x | -234.11% |
| 2024-10-31 | $272.61 Million | $-48.28 Million | -0.177x | +48.12% |
| 2023-10-31 | $72.49 Million | $-24.74 Million | -0.341x | -147.25% |
| 2022-10-31 | $127.42 Million | $-17.59 Million | -0.138x | -10.03% |
| 2021-10-31 | $127.39 Million | $-15.98 Million | -0.125x | -- |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more